When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Exagamglogene autotemcel - Wikipedia

   en.wikipedia.org/wiki/Exagamglogene_autotemcel

   UNII. S53L777GM8. KEGG. D12749. Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [1][3] and transfusion-dependent beta thalassemia. [1] It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

3. FDA approves cure for sickle cell disease, the first ... - AOL

   www.aol.com/news/fda-approves-cure-sickle-cell...

   The FDA on Friday also approved a second treatment for sickle cell disease, called Lyfgenia, a gene therapy from drugmaker Bluebird Bio. Both treatments work by genetically modifying a patient’s ...

4. Promising new gene therapies for sickle cell are out of reach ...

   www.aol.com/news/promising-gene-therapies-sickle...

   The price tags for the two sickle cell therapies in the U.S. are $3.1 million and $2.2 million although the cost for gene therapies can vary by country. ... Dongre said he hopes gene therapy for ...

5. Lovotibeglogene autotemcel - Wikipedia

   en.wikipedia.org/wiki/Lovotibeglogene_autotemcel

   Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease. [1] [3] [4] [5]The most common side effects include stomatitis (mouth sores of the lips, mouth, and throat), low levels of platelets, white blood cells, and red blood cells, and febrile neutropenia (fever and low white blood cell count), consistent with ...

6. New sickle cell treatment sparks feelings of hope and some ...

   www.aol.com/news/sickle-cell-treatment-sparks...

   The Food and Drug Administration must decide by Friday whether to approve a new gene-editing therapy to treat sickle cell disease, a debilitating blood disorder that affects at least 100,000 ...

7. Betibeglogene autotemcel - Wikipedia

   en.wikipedia.org/wiki/Betibeglogene_autotemcel

   KEGG. D11930. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [1][5][2] It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015. [6][7] The most common adverse reactions include reduced platelet ...